HIGHLIGHTS
- who: Aurelie Garant and collaborators from the Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USADepartment of Surgery, Jewish General Hospital, McGill University, Montreal, QC H T, Canada have published the research: MORPHEUS Phase II-III Study: A Pre-Planned Interim Safety Analysis and Preliminary Results, in the Journal: (JOURNAL)
- what: In this first interim analysis, the authors compare toxicity and TME-free survival between IGAEBT and EBRT treatment arms. In this trial, 40 patients were randomized and are presented in a CONSORT diagram . In the opinion , the adaptive real-time boost planning . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.